viewBraveheart Investment Group

Investment in Pharm2Farm Limited

/**/ link{ color: blue }visited{ color: #954F72 } .q{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.q{}p.ah{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right; text-autospace: none}span.af{color:black}p.ai{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center; text-autospace: none}span.ad{font-size:14.0pt;color:black}p.aj{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-autospace: none}p.ak{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal;text-autospace:none}p.al{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}span.y{color:blue} p.am{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}table.an{margin-left:auto;margin-right:auto;width:460.7pt;border-collapse:collapse}td.v{width:322.35pt;padding:0cm 5.4pt 0cm 5.4pt}p.ao{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}td.u{width:116.75pt;padding:0cm 5.4pt 0cm 5.4pt}p.ap{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";} /**/
RNS Number : 7146E
Braveheart Investment Group plc
08 July 2019

8 July 2019


Braveheart Investment Group plc

("Braveheart" or the "Group")


Investment in Pharm2Farm Limited


Braveheart (AIM: BRH), the fund management and strategic investor group, is pleased to announce that it has acquired a 33 per cent. holding in Pharm2Farm Limited ("P2F"). P2F is a spin out from Nottingham Trent University ("NTU") and is based in Nottingham, UK.


NTU and P2F have developed and patented a process to increase the bioavailability of trace minerals in plant feeds. Their patented process uses nanotechnology to dramatically improve trace element take-up in both flower and crop farming. P2F produce and sell these products through an exclusive licence to this technology from NTU.


Since records began in the 1940's, the nutritional value of the UK's and worldwide crops has diminished dramatically. Many of the intensively grown foods produced can no longer be regarded to be 'as healthy' because they lack the levels of trace elements once present. P2F produces these specialist nutrients in a unique way so that plants can absorb them more effectively.


This pioneering technology was initially developed to enrich the nutritional value of potatoes, in conjunction with the Agriculture and Horticulture Development Board ("AHDB") which represents farmers. Preliminary results not only showed a 20 per cent. increase in iron uptake by the tubers, but also an increase in yield and an approximate two-week reduction in the time to harvest. This patented technology has now been developed for use in the growing of other commercial crops, both in soil and hydroponically.


The worldwide hydroponics market alone is estimated to be $8.1 billion in 2019 and is expected to continue to grow at a compound annual growth rate of over 12 per cent. to $16.0 billion by 2025, with the EU remaining the largest market for hydroponically produced crops.

The Board of Braveheart believes there is a substantial market opportunity for this technology and is in negotiations to take the Group's shareholding in P2F to 54 per cent. by way of a working capital investment.



For further information:


Braveheart Investment Group plc
Trevor Brown, Chief Executive Officer



Tel: 01738 587555

Allenby Capital Limited (Nominated Adviser and Joint Broker)
David Worlidge / Nicholas Chambers


Tel: 020 3328 5656



Peterhouse Capital Limited (Joint Broker)
Heena Karani / Lucy Williams


Tel: 020 7469 0936


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Braveheart Investment Group

Price: 10.5

Market: AIM
Market Cap: £2.95 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Braveheart's Trevor Brown details investment in 'exciting' Pharm2Farm Limited

Proactive London's Andrew Scott speaks to Braveheart Investment Group PLC's (LON:BRH) and Pharm2Farm Limited's (P2F) Gareth Cave following Braveheart's investment in the business. P2F has developed a patented process to increase the bioavailability of trace minerals in plant feeds for...

on 15/7/19